Kinase Inhibitor Indole Derivatives as Anticancer Agents: A Patent Review

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Oncology

Background:

• Cancer remains a leading cause of mortality, necessitating novel therapeutic strategies.
• Developing new anticancer agents is crucial for effective disease prevention and treatment.
• Indole scaffolds represent a promising structural motif for anticancer drug design.

Purpose of the Study:

• To review patented indole-based anticancer druglike molecules.
• To explore the targeting of various biological sites, particularly kinases, by these indole derivatives.
• To summarize the mechanism of action and inhibitory potential of indole compounds against specific kinases.

Main Methods:

• Literature review of patents involving indole derivatives as anticancer agents.
• Analysis of kinase targets, including receptor tyrosine kinases (e.g., VEGFR, FGFR), non-receptor tyrosine kinases (e.g., BTK, ALK, JAK), serine/threonine kinases (e.g., CDKs, Aurora kinases), and lipid kinases (e.g., PI3K).
• Summary of structure-activity relationships and the impact of substituent modifications on pharmacokinetic and pharmacodynamic properties.

Main Results:

• Indole derivatives have been patented as potent inhibitors of a wide array of kinases implicated in cancer.
• Specific examples include inhibitors targeting kinases like VEGFR, FGFR, BTK, ALK, JAK, CDKs, and Aurora kinases.
• The indole core serves as a versatile scaffold for developing kinase inhibitors with tunable properties.

Conclusions:

• The indole nucleus is a valuable foundation for designing novel anticancer drugs, particularly kinase inhibitors.
• Modification of indole substituents can significantly influence drug efficacy and drug-like properties.
• Further research into indole-based compounds holds potential for developing new anticancer therapies targeting diverse biological pathways.